Overview

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, non-randomized, single arm, 2 parts, phase II clinical trial evaluating the efficacy and safety of pembrolizumab and lenvatinib plus standard of care chemotherapy (with carboplatin and etoposide ) in subjects with histologically confirmed extensive-stage small-cell lung cancer who have not previously received systemic therapy for this malignancy.

Phase:

Phase 2

Details

Lead Sponsor:

Fundación GECP

Treatments:

Carboplatin
Etoposide
Etoposide phosphate
Lenvatinib
Pembrolizumab